当前位置: X-MOL 学术Knee Surg. Sports Traumatol. Arthrosc. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Matrix-associated stem cell transplantation is successful in treating talar osteochondral lesions.
Knee Surgery, Sports Traumatology, Arthroscopy ( IF 3.8 ) Pub Date : 2019-03-20 , DOI: 10.1007/s00167-019-05452-z
Evelyn P Murphy 1 , Christopher Fenelon 1 , Ciara Egan 1 , Stephen R Kearns 1
Affiliation  

PURPOSE Osteochondral lesions (OCLs) of the talus are a challenging and increasingly recognized problem in chronic ankle pain. Many novel techniques exist to try and treat this challenging entity. Difficulties associated with treating OCLs include lesion location, size, chronicity, and problems associated with potential graft harvest sites. Matrix-associated stem cell transplantation (MAST) is one such treatment described for larger lesions > 15 mm2 or failed alternative therapies. This cohort study describes a 3 year review of the outcomes of talar lesions treated with MAST. METHODS A review of all patients treated with MAST by a single surgeon was conducted. Pre-operative radiographs, MRIs, and FAOS outcome questionnaire scores were reviewed. Intraoperative classification was undertaken to correlate with imaging. Post-operative outcomes included FAOS scores, return to sport, revision surgery/failure of treatment, and progression to ankle fusion. RESULTS In this study, 38 OCLs in 32 patients were identified. Median patient age was 35 years of which (68.8%) were male. Median length of follow-up was 36.7 months (range 12-64 months). (83%) returned to playing sport. Twenty-three patients underwent MAST in the setting of a failed previous operative attempt, with just nine having MAST as a first option. Nine patients out of 32 had a further procedure. Improvements were seen in all domains of the FAOS (p < 0.05). CONCLUSION MAST has demonstrated encouraging results in lesions which prove challenging to treat, even in a "failed microfracture" cohort. LEVEL OF EVIDENCE IV.

中文翻译:

基质相关的干细胞移植成功治疗距骨骨软骨病变。

目的距骨的骨软骨损伤(OCL)是慢性脚踝疼痛中一个具有挑战性且日益为人们所认识的问题。存在许多尝试去治疗这种具有挑战性的实体的新颖技术。与治疗OCL有关的困难包括病变部位,大小,慢性以及与潜在的移植物收获部位有关的问题。基质相关的干细胞移植(MAST)是针对大于15 mm2的较大病灶或替代疗法失败而描述的一种此类治疗方法。这项队列研究描述了对用MAST治疗的距骨病变的结局进行为期3年的回顾。方法对由一名外科医生治疗的所有MAST患者进行回顾。回顾了术前X光片,MRI和FAOS结果问卷评分。进行术中分类以与影像学相关。术后结果包括FAOS评分,恢复运动,翻修手术/治疗失败以及踝关节融合进展。结果在本研究中,鉴定出32例患者中的38个OCL。中位患者年龄为35岁,其中男性为68.8%。中位随访时间为36.7个月(范围12-64个月)。(83%)重返体育运动。在先前手术尝试失败的情况下,有23例患者接受了MAST,其中只有9例接受MAST作为首选。32名患者中有9名接受了进一步的手术。在粮农组织驻国家代表处的所有领域都有所改善(p <0.05)。结论MAST已显示出令人鼓舞的结果,即使在“失败的微骨折”队列中,也难以治疗。证据级别IV。并发展为脚踝融合。结果在本研究中,鉴定出32例患者中的38个OCL。中位患者年龄为35岁,其中男性为68.8%。中位随访时间为36.7个月(范围12-64个月)。(83%)重返体育运动。在先前手术尝试失败的情况下,有23例患者接受了MAST治疗,其中只有9例接受了MAST治疗。32名患者中有9名接受了进一步手术。在粮农组织驻国家代表处的所有领域都有所改善(p <0.05)。结论MAST已显示出令人鼓舞的结果,即使在“失败的微骨折”队列中,也难以治疗。证据级别IV。并发展为脚踝融合。结果在本研究中,鉴定出32例患者中的38个OCL。中位患者年龄为35岁,其中男性为68.8%。中位随访时间为36.7个月(范围12-64个月)。(83%)重返体育运动。在先前手术尝试失败的情况下,有23例患者接受了MAST,其中只有9例接受MAST作为首选。32名患者中有9名接受了进一步的手术。在粮农组织驻国家代表处的所有领域都有所改善(p <0.05)。结论MAST已显示出令人鼓舞的结果,即使在“失败的微骨折”队列中,也难以治疗。证据级别IV。中位随访时间为36.7个月(范围12-64个月)。(83%)重返体育运动。在先前手术尝试失败的情况下,有23例患者接受了MAST,其中只有9例接受MAST作为首选。32名患者中有9名接受了进一步的手术。在粮农组织驻国家代表处的所有领域都有所改善(p <0.05)。结论MAST已显示出令人鼓舞的结果,即使在“失败的微骨折”队列中,也难以治疗。证据级别IV。中位随访时间为36.7个月(范围12-64个月)。(83%)重返体育运动。在先前手术尝试失败的情况下,有23例患者接受了MAST,其中只有9例接受MAST作为首选。32名患者中有9名接受了进一步的手术。在粮农组织驻国家代表处的所有领域都有所改善(p <0.05)。结论MAST已显示出令人鼓舞的结果,即使在“失败的微骨折”队列中,也难以治疗。证据级别IV。结论MAST已显示出令人鼓舞的结果,即使在“失败的微骨折”队列中,也难以治疗。证据级别IV。结论MAST已显示出令人鼓舞的结果,即使在“失败的微骨折”队列中,也难以治疗。证据级别IV。
更新日期:2019-03-19
down
wechat
bug